of and recent for to everyone, joining also the to morning, we'd for second pleased updates, Good take be then us Rob. some to review any our Thanks, thanks cover financial results 'XX questions. quarter and
more interim the we to or C. by ibezapolstat have antibiotic patients enrolled now of we patients Xb the purpose, quarter Xb enroll ‘XX We're the Independent review trial of data Data continued to Phase pleased lead report for only CDI. XX with difficile first in of appointed XXXX, Phase infection candidate to our Monitoring clinical in of second that treatment be quarter to five trial. In we patients patients It's an in the this for more trigger the need enrolled Committee
IDMC data the for the alternatively Phase we endpoint had patient the or early The of being and at Xa XX properly trial will trial clinical Xb the either terminate provide the enrolling. recommendation review upon with cure us evaluated treatment primary continue of the end to done to as
in early review the the and the the recommendation report of Xb the the we report if the will after endpoint IDMC IDMC treatment, primary will data, the coming two. review anticipate – data patients patient and interim the trial, XX safety completing data enrolled interim XX the We the or top-line for recommends month completes termination of enrollment we properly of when patient
an between to pleased signals and phase includes exploratory with the the standard-of-care we're the observe endpoint report trial trial that expected oral the data ibezapolstat reported Operationally, is as no the Xb trial been on exceptional Phase from safety The and impact vancomycin. proceeding has to-date. comparing Xb microbiome protocol blinded
increased of XX than In we the did couple further conducted aftermath, superiority. the its the screening trial increased we as XX during demonstrated, from be to of and is expected ibezapolstat pandemic test to have up sites sites and in will Vancomycin COVID-XX months. event higher analysis now Due enrolling sites non-inferiority for the sites the slower resulting to Xb the in past expand participating support have to to initial number of enrollment, in to trial
that's to accepted an to Independent the the allow Data Monitoring interim FDA XXXX, our data FDA. March protocol review IND, Committee pre-cleared will the our amendment In which with been
impact dual long-term the microbiome, treat the about while of we same care acute time the which infection, the each excited of particularly is appropriately the C believe managing remain to ibezapolstat diff therapy. for antibiotic patient's infection at We exceptional
Chair highlights program. in year of was this two include Reduced with diff poster diff Clinical presented entitled Microbiome Gary, Antibiotics” Ibezapolstat Congress or for April the by decided cases Professor Isolates Microbiology Houston to “Novel thereafter Pharmacology Dr. of Principal or of to the some Investigator Other College Pharmacy made European Directed key Aspects our and Copenhagen, following: the In the ‘XX shortly quarter ibezapolstat and and and C. Susceptibility in clinical C. University of Infectious Susceptibilities presentations of from Kevin at the Annual Against second of of were first ECCMID XX Disease
C. diff of also After noted C.diff are reduced fidaxomicin, of work, C. to susceptibility antibiotics demonstrated is not its with bactericidal other the virulence some capability that could to strains to cause to also Gary diff, susceptible disease. or only action were inhibit that Dr. treat strains Gary's C. ibezapolstat’s its to ibezapolstat. mechanisms those but diff, any metronidazole of meaning vancomycin to used mechanism
of diff the unexpected DNA So kill to many reflecting just IIIC. antibiotics the to inhibiting organism bacteria able other again, C. is to cases used of the finding, C. and pol is diff C. was diff reduced a treat in action unique movement effect say Ibezapolstat’s that resistant ibezapolstat antivirulence flagellar currently. mode successfully it positive namely to all
program Chairman, In the SX of other caused second "Pipeline DeLuccia, Executive infections systemic organized Corner" MRSA, company's Both by IV at Bob featured VRE and in update discovery gram-positive preclinical, website. progress and world-renowned a at the of ECCMID posters positive at Company's Select presentations Acurx by policies an for DRSP Bob Spectrum public the strategies needs. clinical for session presented treatment research, oral gram- and summarized regarding Dr. drug a health Program. antibacterial on available Ursula the involved development our and and Theuretzbacher, are ECCMID, expert microbiology
funding ACXXXXC, development. this in round did the not for omni-bus candidate is third ‘XX notified receive modifications our by CARB-X the our to funding of we appeal second based recently Additionally, program. we scope were their We antibiotic in preclinical on that decision closed certain in approval quarter, did which
appeal of not an However, for governance allow process. CARB-X structure acceptance did
compounds of funding that the that target their the was good Board have Pol and that proposed to from was bacterial funding our plan. of a the noted justified Requests the safety for Advisory to properties ‘XX enthusiastic CARB-X will we time-to-time PK us Proposals and about molecules future competitive lead sufficiently consideration. RFPS optimization Scientific that of and IIIC very promulgate as continue for reapply round that's or encourage CARB-X For CARB-X
grants and this While news disappointing, for apply from funding sources as was continue to become monitor available. all will we they
bit, will present will Pol combating Executive sectors our at looking an convene now upcoming next is in showcase conference to Infections in Next for just, just Chairman available be “Novel Annual of world's Gram-Positive resistance the the update After website. on Philadelphia antimicrobial presentation Meeting entitled from latest Antimicrobial on experts month. will Congress innovation Pandemic”. fields all in It and the section largest IIIC the Preparing on public Resistance Inhibitors the stakeholders the for weigh resistance. it private the innovations a address our Now, DNA and antimicrobial conference Bacteria This speak and the the Xth both will its forward is where September for
will IDWeek coming two Society Meeting to the have in XX. will October events. Acurx featured Infectious we scheduled XX be its up, addition, IDWeek Boston, America Disease of In at called convene Annual
Symposium Dr. the ibezapolstat presentation will oral Elucidating DNA in Kevin Pol “New Acurx will an be Selective entitled October Positive At entitled Antimicrobials presentation Spectrum the Bacterial Inhibitors Phase XX. entitled given secondly, IIIC Activity Gram website. will For October Acurx The First, And of Analysis this available at our this Infections”. from it After present Gary XXth be Pipeline” be symposium, trial. the “Novel by Gram-positive’s on on Secondary Xa presentation on will too
Now the PASTEUR to Act.
XXth, of continues in developments news improve availability in the domestic As Bipartisan encourage Michael in Washington On Bennet the most when needed. targeting drug innovative Act Young Act Todd generate use ensure enthusiasm Senators antibiotics reintroduced PASTEUR threatening and - we've appropriate discussed April, of DC. antibiotics past, the the to and to the drugs PASTEUR US infections, and
On including C. to hearing Antimicrobial address and highlighting, need a Senate and Markey the and diff. July Marshall Bugs, Resistance Senators Subcommittee convened was led XXth, Super MRSA, the by to
Accordingly, antibiotics to of PASTEUR Bipartisan passed national being Act law and significant on the new into serious for about enthusiastic support the infections. the classes quite need treat prospects of spotlight we're life-threatening and dire
the And to through now quarter back our XXXX. financial Shawah CFO, second guide highlights of of to for Rob? the results you Rob our
